Directorate Change

Surgical Innovations Group PLC
19 December 2023

Surgical Innovations Group Plc

 ("Surgical Innovations", the "Company" or the "Group")


Directorate Change


Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, announces that Charmaine Day has notified the Board of her intention to step down from her role as Chief Financial Officer ('CFO') and Company Secretary in order to pursue other opportunities.


The Company will begin an extensive search to find the correct candidate for the CFO position and an orderly transition process will take place, aided by Charmaine, ahead of her departure from Surgical Innovations. Charmaine has committed to stay until the transition to her successor is complete.


CEO, David Marsh, commented: "It has been a pleasure to work with Charmaine since she joined Surgical Innovations in 2012, and especially in the role of CFO since 2021, and I would like to thank her for the excellent and continued contribution that she brings to the business.


"We will begin the search imminently to find a new CFO and will effect an orderly handover once the right candidate has been selected, with both aspects of the transition supported by Charmaine. We look forward to providing an update in due course."


The Company's next scheduled trading update will be late January 2024


For further information please contact:


Surgical Innovations Group plc

www sigroupplc com

David Marsh, CEO

Charmaine Day, CFO

Tel: 0113 230 7597

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Oliver Platts

Walbrook PR (Financial PR & Investor Relations)

Tel: 020 7933 8780 or

Paul McManus / Charlotte Edgar / Alice Woodings

Mob: 07980 541 893 / 07584 391 303 / 07407 804 654



About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.


We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.


Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.


In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.


We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.


Further information

Further details of the Group's businesses and products are available on the following websites:


To receive regular updates by email, please contact  



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100

Latest directors dealings